Descrizione del progetto
Immunizzazione passiva come strategia per trattare l’infezione da coronavirus
L’immunizzazione passiva di breve durata come terapia anti-Covid-19 appare immediatamente necessaria per appiattire la curva dell’infezione e fornire tempo per gli approcci di immunità di gregge. La strategia richiede la valorizzazione dell’estrema eterogeneità della risposta immunitaria antivirale umana. La società irlandese Remedy Biologics ha sviluppato una piattaforma per analizzare rapidamente e simultaneamente milioni di singole cellule immunitarie produttrici di anticorpi da un singolo campione. Essa offre l’opportunità di identificare i migliori anticorpi del sistema immunitario di convalescenti Covid-19 da utilizzare nella creazione di terapie passive per pazienti critici. Il progetto RapCo-19, finanziato dall’UE, si propone di combinare nuove tecnologie di scoperta per creare una piattaforma per la rapida identificazione e produzione di anticorpi neutralizzanti anti-virali contro la Covid-19.
Obiettivo
The SARS-CoV-2 pandemic requires the most serious and rapid healthcare response seen in modern history. The lag time between the emergence of the pathogen and the implementation of a licensed vaccine still remains an obstacle for prophylactic measures. In addition, how long immunity lasts for following COVID-19 infection is a big unknown. The development of immunity to the currently circulating SARS-CoV2 may not provide sterilising protection against subsequent coronavirus infections. If this were to be confirmed, it would add to the challenge of managing the pandemic.
Short-lived passive immunisation with an anti-COVID-19 therapy is immediately required to treat infected patients and to ‘flatten the infection curve’ and to provide time for ‘herd immunity’ approaches. Devising an effective strategy requires an approach that is designed to exploit the extreme heterogeneity of the human anti-viral immune response.
RemedyBio’s Nanoreactor technology is such a system. It is the result of a 5-year research programme to develop a platform to rapidly and simultaneously analyse millions of single antibody-producing immune cells from an individual sample. In the context of COVID-19, this presents an opportunity to rapidly identify the best antibodies from the immune systems of COVID-19 convalescent patients from which to create a rapid passive therapeutic for those that are critically ill from the virus.
Based on records from 1918/1919, it is plausible for the COVID-19 pandemic to wane in the late spring (in Europe), and come back as a second wave in the winter, which, as was the case in 1918, could be even worse than what we're facing now. COVID-19 is a global health problem and we need to be ready for this. This project is designed to combine novel discovery and delivery technologies to form a platform to rapidly identify, produce and deliver anti-viral neutralising antibodies to COVID-19.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-EIC-SMEInst-2018-2020-3
Meccanismo di finanziamento
SME - SME instrumentCoordinatore
A84R970 ASHBOURNE CO MEATH
Irlanda
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.